|
|
Article: NasVax Announces Positive Results from Preclinical Testing of Swine Flu Vaccine using its Novel Adjuvant.
- Article from:
- Vaccine Weekly
- Article date:
- November 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NasVax Ltd. (TASE: NSVX), an Israeli company developing new and improved vaccines and immunotherapeutics, reports positive preclinical results for a swine influenza H1N1 vaccine formulated with its unique VaxiSomeTM liposome-based adjuvant (see also H1N1 Virus).
The efficacy of different dosage levels of (H1N1)v A/California/7/2009 antigen administered intramuscularly to mice was compared to corresponding dosage levels of the antigen formulated with two different levels of VaxiSome. Efficacy was evaluated by assaying the level of serum antibody (HI = Hemagglutinin Inhibiting) response post dose-one and post dose-two, where HI antibodies are considered a surrogate ...